TCR-T
Phase 1Cell therapy
TCR-T is one of 45 biologic programs targeting Chronic Hepatitis. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
71 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1Hepsera
GileadApproved
PEG-Intron
Merck & Co.Phase 3
Emtriva
GileadApproved
PEGASYS
Ppharmaand GmbH
Approved
Opdivo
Bristol-Myers SquibbPhase 2
Pegylated Interferon Alfa
Merck & Co.Phase 3
NA Therapy
GSKPhase 3
AHB-137
AAusper Biopharma Co., Ltd.
Phase 3
Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
Azvudine
HHenan Genuine Biotech Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis1 trial
Autologous T-cells Transfected With mRNA Encoding HBV-TCR T Cell Therapy in Combination With NUC for Chronic Hepatitis B
Active, not recruiting·—·Phase 1·NCT05905731·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TCR-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- LLion TCR Pte. Ltd.